NetworkNewsBreaks – Flora Growth Corp. (NASDAQ:
Post# of 278
(Total Views: 163)
Posted On: 02/02/2022 2:42:41 PM
NetworkNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Seeks Approval to Study Patent-Pending Cannabinoid-Based Product to Treat COVID-19
Flora Growth’s (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is hoping to begin research on its patent-pending, cannabinoid-based product. The company is requesting approval from INVIMA, the Colombian FDA, noting that recent studies indicate the potential for cannabinoids to display viral inhibition. FLGC’s research division, Flora Pharma, has filed a USPTO provisional patent application regarding the company’s cannabinoid-based formula, and the company is hoping to take the product through clinical trials under an emergency use authorization (“EUA”) from INVIMA.According to the company, the intent of the study is to identify safe and efficacious cannabinoid products for use on SARS-CoV-2 (COVID-19); FLGC plans to pursue the fastest path to market via a preventative immunomodulating product and to explore the possibility of use as a therapeutic. If the company’s request is approved, Flora’s formulation would be the first product containing cannabinoids to be approved for use against COVID-19 by the Colombian government. “We are honored to receive the advice and guidelines from INVIMA as we begin this exciting research process,” said Flora Growth president and CEO Luis Merchan in the press release. “The Flora Pharma division seeks to obtain evidence to support this product’s use against SARS-CoV-2 and bring to market an effective, cannabinoid-based product. . . . At Flora Growth, we believe in following the research, and there have been several promising studies published in just the last few months on the application of cannabinoids in certain treatments. We are excited for our Flora Pharma researchers to build upon this progress and generate new data for how cannabis could help consumers around the world, leveraging this natural, botanical alternative.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Flora Growth’s (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is hoping to begin research on its patent-pending, cannabinoid-based product. The company is requesting approval from INVIMA, the Colombian FDA, noting that recent studies indicate the potential for cannabinoids to display viral inhibition. FLGC’s research division, Flora Pharma, has filed a USPTO provisional patent application regarding the company’s cannabinoid-based formula, and the company is hoping to take the product through clinical trials under an emergency use authorization (“EUA”) from INVIMA.According to the company, the intent of the study is to identify safe and efficacious cannabinoid products for use on SARS-CoV-2 (COVID-19); FLGC plans to pursue the fastest path to market via a preventative immunomodulating product and to explore the possibility of use as a therapeutic. If the company’s request is approved, Flora’s formulation would be the first product containing cannabinoids to be approved for use against COVID-19 by the Colombian government. “We are honored to receive the advice and guidelines from INVIMA as we begin this exciting research process,” said Flora Growth president and CEO Luis Merchan in the press release. “The Flora Pharma division seeks to obtain evidence to support this product’s use against SARS-CoV-2 and bring to market an effective, cannabinoid-based product. . . . At Flora Growth, we believe in following the research, and there have been several promising studies published in just the last few months on the application of cannabinoids in certain treatments. We are excited for our Flora Pharma researchers to build upon this progress and generate new data for how cannabis could help consumers around the world, leveraging this natural, botanical alternative.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)